Navigation Links
At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
Date:9/16/2013

EXTON, Pa., Sept. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at one month post-launch of Algeta/Bayer HealthCare's Xofigo in the United States, approximately one quarter of surveyed U.S. medical oncologists indicated that they have prescribed Xofigo. According to the first wave of the LaunchTrends® Xofigo report series, nearly half of current non-prescribers stated that they would prescribe Xofigo in the next four to six months. Notably, the majority of current non-prescribers indicated that they would prescribe Xofigo to both their docetaxel-naive and docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC) patients.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The report also finds that over half of surveyed medical oncologists reported high favorability toward Xofigo, and a majority of respondents indicated a high level of interest in Xofigo. For docetaxel-naive mCRPC, the highest proportion of surveyed medical oncologists indicated that the bone-targeted mechanism of action of Xofigo and its safety profile are among the main advantages of the agent. For docetaxel-pretreated mCRPC, the main perceived advantages of Xofigo over Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga and Medivation/Astellas Pharma's Xtandi lie in Xofigo's limited and fixed treatment duration and the fact that it is an efficacious bone-targeted agent, according to surveyed medical oncologists.

"Surveyed medical oncologists cited the need to refer patients to a licensed nuclear medicine facility as one of the main disadvantages of Xofigo compared to other agents used to treat docetaxel-naive and docetaxel-pretreated mCRPC," said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz, M.Sc. "We also find that just over half of Xofigo non-prescribers indicated that they are aware of the nearest location licensed for Xofigo administration."

LaunchTrends: Xofigo (US) is a three-wave syndicated report series designed to track the uptake of Xofigo at one month, six months and one year following Xofigo's commercial availability, based upon primary research with U.S. medical oncologists. LaunchTrends assess trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. For this first wave of research, BioTrends surveyed 75 U.S. medical oncologists and conducted qualitative interviews with 13 U.S. medical oncologists in July 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
2. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
3. Inaugural National Mobility Awareness Month Commences in May Saluting the More than 18 Million with Disabilities
4. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
5. eCardio Teams Up with Heart Rhythm Society for Month-Long Campaign to Raise Awareness of Cardiac Arrhythmias
6. Herborium Group Reports Record 6 Month Revenues
7. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
8. Regional Medical Center at Memphis Completes Rapid Six-Month Implementation of Comprehensive Perioperative and Anesthesia Solution from Surgical Information Systems
9. Bacterin International Announces Second Quarter and Six Months 2012 Financial Results
10. Comprehensive Care Corporation Announces Profitable Six Month Financial Results
11. Dehaier Medical Announces 2012 Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 According to a ... Computer Interface Market - Global Industry Analysis, Size, Share, ... computer interface (BCI) market  is expected to reach a ... estimated to expand at a CAGR of 14.9 % ... A BCI device provides collaboration between the brain ...
(Date:5/4/2016)... In March, 2016, Rx-360 ... free workshops across Africa ... Good Distribution Practices (GDP). Good Distribution Practice is ... are consistently stored, transported and handled under suitable conditions as ... Only a few years ago, there were few ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Actinic Keratosis ...  report to their offering.       ... Actinic Keratosis Market and Competitive Landscape Highlights ... pipeline products, Actinic Keratosis epidemiology, Actinic Keratosis ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Is the part in your hair widening? Are ... days away, it’s a good opportunity to raise awareness about a common condition among ... Dermatology, 40% of women experience hair loss or ‘thinning’ by the time they reach ...
(Date:5/4/2016)... ... May 04, 2016 , ... ProList is a set of 30 self-animating bullet ... ProList, editors can easily create lists for presentations, youtube productions, and more. Simply ... ProList is the perfect complement to presentation style videos. , ProList is a package ...
(Date:5/4/2016)... ... May 04, 2016 , ... Qualitative research, which ... add a deeper understanding of the program, policy or intervention being studied. Both ... yet important questions. , In a new brief released today, Reading Qualitative Educational ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Business Conference. The conference opened on Tuesday with Frank Luntz, sharing a dynamic, ... PDMP Solution provided a deep dive on NCPDP’s model solution to help stem ...
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute announces ... of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses ... 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we are raising ...
Breaking Medicine News(10 mins):